Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios Anagnostopoulos

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Haematologica|December 7, 2005
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomibMeletios A Dimopoulos, Athanasios Anagnostopoulos, Maria Christina Kyrtsonis, et al.
Cancer|June 16, 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaAthanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, et al.
Leukemia & Lymphoma|January 19, 2008
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphomaTheofanis Economopoulos, Amanda Psyrri, George Fountzilas, et al.
British Journal of Haematology|April 25, 2007
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severityAthanasios Anagnostopoulos, Vangelis Eleftherakis-Papaiakovou, Efstathios Kastritis, et al.
Leukemia & Lymphoma|June 30, 2004
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemiaMeletios Dimopoulos, Dimitra Gika, Konstantinos Zervas, et al.
Clinical Lymphoma|March 30, 2005
Predictive factors for response to rituximab in Waldenstrom's macroglobulinemiaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Constantinos Zervas, et al.
Urology|September 8, 2004
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupHelena Linardou, Gerassimos Aravantinos, Eleni Efstathiou, et al.
British Journal of Haematology|August 26, 2004
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)Marianna Politou, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
International Journal of Cancer|April 29, 2006
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantationMarianna C Politou, Deborah J Heath, Amin Rahemtulla, et al.
Haematologica|May 10, 2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agentsEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Haematologica|December 7, 2005
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomibMeletios A Dimopoulos, Athanasios Anagnostopoulos, Maria Christina Kyrtsonis, et al.
Cancer|June 16, 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaAthanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, et al.
Leukemia & Lymphoma|January 19, 2008
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphomaTheofanis Economopoulos, Amanda Psyrri, George Fountzilas, et al.
British Journal of Haematology|April 25, 2007
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severityAthanasios Anagnostopoulos, Vangelis Eleftherakis-Papaiakovou, Efstathios Kastritis, et al.
Leukemia & Lymphoma|June 30, 2004
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemiaMeletios Dimopoulos, Dimitra Gika, Konstantinos Zervas, et al.
Clinical Lymphoma|March 30, 2005
Predictive factors for response to rituximab in Waldenstrom's macroglobulinemiaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Constantinos Zervas, et al.
Urology|September 8, 2004
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupHelena Linardou, Gerassimos Aravantinos, Eleni Efstathiou, et al.
British Journal of Haematology|August 26, 2004
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)Marianna Politou, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
International Journal of Cancer|April 29, 2006
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantationMarianna C Politou, Deborah J Heath, Amin Rahemtulla, et al.
Haematologica|May 10, 2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agentsEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Pageof 6